Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes
| Autor: | Bjorn Bolinder, Stuart A. Ross, Elmar Stridde, L. Martinez, Lawrence Blonde, FD Richard Hobbs, Didier Duhot, Marcus Hompesch, Nick Freemantle, Robert Eggertsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes law.invention Randomized controlled trial Informed consent law Internal medicine Diabetes mellitus Administration Inhalation Internal Medicine medicine Humans Hypoglycemic Agents Insulin In patient Risks and benefits Aged Aged 80 and over Advanced and Specialized Nursing business.industry Inhaled insulin Middle Aged Patient Acceptance of Health Care medicine.disease Diabetes Mellitus Type 2 Physical therapy Female business |
| DOI: | 10.2337/diacare.28.2.427 |
| Popis: | Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled trial examined the extent to which the availability of INH affects the perceived acceptability of insulin therapy among patients with type 2 diabetes who failed to achieve target glycemia on current therapy. Male or female participants ( n = 779) aged 35–80 years with at least 3 months duration of type 2 diabetes and a HbA1c >8%, despite current therapy, were recruited from seven countries. Permitted current therapy included dietary measures and/or oral antidiabetic agents (OADs). Patients receiving insulin injections, smokers, or those who had significant pulmonary diseases were excluded. All patients gave informed consent, and local research ethics review boards approved the study. Participants were randomly assigned to receive either educational information about the potential risks and benefits of all currently licensed treatment options only (OADs and/or subcutaneous insulin, n = 388) or information about the potential risks and benefits of licensed treatments and INH ( n = 391). … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|